Molecular Partners AG
NASDAQ:MOLNBiotechnology
+$0.03 today
- Market cap
- $100.28M
- Beta
- 0.71
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.55
Volume 0.00M
Average 0.00M
Returns on capital
Molecular Partners AG management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-76.7%
avg -32.8%
ROIC
-63.0%
avg -25.6%
ROA
-60.4%
avg -21.6%
Analysis
ROA is currently the strongest return metric at -60.4% versus its period average of -21.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Patrick Amstutz | Co-Founder, Chief Executive Officer, Member of Management Board & Director | CHF 797.05K | 51 | — | — |
Alexander Zurcher | Chief Operating Officer & Member of Management Board | — | 51 | — | — |
Daniel Steiner | Senior Vice President of Targeted Radio Therapeutics | — | — | — | — |
Martin Steegmaier | Chief Scientific Officer & Member of the Management Board | — | 60 | — | — |
Michael Pitzner | Executive VP of Partnering & General Counsel | — | — | — | — |
Robert Hendriks | Senior VP of Finance & Member of Management Board | — | — | — | — |
Renate Gloggner | Executive Vice President of People & Community and Member of Management Board | — | 56 | — | — |
Pamela A. Trail | Strategic Consultant | — | 70 | — | — |
Philippe Legenne | Chief Medical Officer & Member of the Management Board | — | 60 | — | — |
Michael Tobias Stumpp | Co-Founder, Executive Vice President of Projects & Member of Management Board | — | 54 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Molecular Partners AG compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about MOLN's management, answered from reported figures.
Who manages MOLN?
Molecular Partners AG (MOLN) lists 10 active executives. The top listed executive is Alexander Zurcher, Chief Operating Officer & Member of Management Board.
Continue the stock analysis
Jump to another research area for this company.